What Kisunla treats.
- Mild cognitive impairment due to Alzheimer’s disease
- Mild Alzheimer’s disease dementia
The mechanism.
Kisunla (donanemab) targets a specific form of amyloid plaque present in Alzheimer’s brains. Unlike some other anti-amyloid therapies, Kisunla can be discontinued once amyloid is cleared on follow-up imaging — offering a defined endpoint to treatment.
Your Kisunla infusion experience.
Kisunla infusions are given every 4 weeks and last about 30 minutes. Periodic amyloid PET scans assess whether plaques have been cleared. Like Leqembi, MRI monitoring is required to detect ARIA, and treatment is limited to early-stage patients.
Insurance & out-of-pocket cost.
Kisunla is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.